Kornimate/medical-research-clean huggingface dataset:
care coordination system for people with dementia

Conditions: Alzheimer Disease; Dementia; Dementia Alzheimers

Summary: dementia, a chronic disease of aging, is characterized by progressive cognitive decline that interferes with independent functioning. the medical, psychological, social and functional sequelae of dementia cause great stress to patients, their caregivers, and their family. the investigator proposes to examine effectivness of a home-based care coordination and management device, called care4ad to help caregivers effectively coordinate, manage, and improve dementia care.

in this study the investigator will assess the effectiveness of a care coordination device (a supportive care device) called, care4ad for reducing burden and stress of caregivers, enhancing patient adherence to scheduled tasks, and increasing individuals with dementia activity (iwd). the investigator will conduct a 6-month prospective randomized control trial (rct) of 100 persons with mild to moderately severe dementia to examine changes in caregiver's burden and stress and iwd's physical activity and adherence to scheduled adls. feedback (e.g., reminders about completed/incomplete tasks) will be activated in the intervention group (ig) and de-activated in the control group (cg). the investigator will also use an adl log and bi-weekly phone interview with a caregiver as gold standards to validate the detection of adherence to scheduled adls of interest. furthermore, the acceptability, perception of benefit, and ease of use of care4ad will be further assessed using technology acceptance model (tam). we hypothesize that at 6 months, those in the ig compared to the cg will have less caregiver burden (zarit burden interview (zbi) (primary outcome), greater iwd adherence to scheduled adls (primary outcome), and higher iwd physical function and activity (primary outcome). secondary outcomes will include caregiver coping (brief cope), self-efficacy (revised scale for caregiving self-efficacy), and preparedness (preparedness for caregiving scale), and quality of life of iwd (quality of life in alzheimer's disease scale)

Eligibility criteria:
inclusion criteria include: * older patients (\> 65 years old) with mild or moderate alzheimer's disease * must be ambulatory * must be in a residential home with a caregiver/informant. exclusion criteria: * immobility or inability to engage in activities that are essential for independent living (e.g., patients with severe dementia); * any significant medical or psychiatric condition that, in the judgment of the investigators, would potentially interfere with the ability to participate in the study * major hearing/visual impairment; * residing in a nursing home or are receiving hospice care; * inability to communicate in english or spanish; * unavailability or unwillingness of the caregiver of the patient to attend the interview.

Keywords: alzheimber dementia care coordination
the effect of live cat and simulation cat therapies on oncology patients

Conditions: Therapy-Associated Cancer; Cancer Patient; Happiness; Symptoms

Summary: it is known that animals are good for humans physiologically and psychologically. therefore, in this study, the effects of live cat and robotic cat therapies on the symptoms and happiness levels of oncology patients after chemotherapy were examined.

cancer is a disease that requires a long-term struggle with the psychosocial and economic burden it creates on the individual, family and society, bringing with it many health problems. although chemotherapy treatment is the main treatment method for patients, it can cause some changes in the individual's appearance while treating cancer and many symptoms such as nausea, vomiting, diarrhea, alopecia, and constipation after treatment. at the same time, patients may feel tired, sleepy and depressed after treatment. however, cancer patients and their families experiencing some unknown diagnosis and treatment processes related to cancer also cause them to be unhappy as a result of experiencing some physical, social, emotional and spiritual problems during the treatment. it is reported in the literature that pet therapy or animal-assisted treatments reduce disease-related symptoms and make patients happy. pet therapy is an auxiliary non-pharmacological form of treatment that heals physiological and psychological diseases through interactions between animals and humans that meet certain criteria, and stimulates and activates the body mechanisms required for the development of the individual's health behaviors. in the literature, pet therapy studies with oncology patients are quite limited. therefore, this study was conducted to examine the effects of live cat and robotic cat therapies on the symptoms and happiness levels experienced by oncology patients after chemotherapy.

Eligibility criteria:
inclusion criteria: * criteria for admission to the study are 18≤ of age, * agreeing to participate in the research, * being conscious of receiving outpatient chemotherapy treatment for 3≤ months, and being able to communicate. * the criteria included no impairment in mental and cognitive functions of patients/relatives in the live group, * patients in the live cat group not having any animal allergies, and the cat group having a cat. exclusion criteria: * not agreeing to participate in the research, * being under 18 years of age, * having known psychological disorders, having a visual, hearing, or speech disability, and having an animal allergy. * also excluded are having a surgical wound (suture, drainage, etc.), neutropenia or severe infection (by resistant bacteria), fever, diarrhea, respiratory symptoms or vomiting during the week before the start of the study.

Keywords: pet therapy cancer patient happiness symptoms
exercise intensity and appetite in adolescents

Conditions: Pediatric Obesity

Summary: acute exercise has been shown to affect subsequent energy intake in obese adolescents. indeed, it has been shown several times that an intensive bout of exercise (above 70% of the individual maximal capacities) can reduce energy intake at the following meal in obese adolescents, with no modification of his appetite feelings. although this results has been replicated several times, it remains unknown if those nutritional adaptations are due to post-exercise modifications of some gastro-peptides implicated in appetite control, as detailed in adults. the aim of this work is to question whether or not post-exercise energy intake is explained by appetite-regulating hormones that are affected by the exercise bout in both lean and obese youth.

after an first medical visit to ensure that the adolescents have the ability to complete the whole study, the participants will have to complete several clinical examinations: * anthropometric measurements * body composition assessed by dual energy x-ray absorptiometry * maximal aerobic test they will then randomly complete the following conditions: * con: a control day without exercise; * hie: an exercise day with an exercise set at 75% of the capacities * lie: an exercise day with an exercise set at 40% of the capacities the exercises or the rest condition will be done by the end of the morning and a buffet meal will be proposed during which the participants will be asked to eat as much as wanted. blood samples will be drawn before, after, 15 after and 30 minutes after the exercise to assess the main appetite regulating hormones involved in appetite regulation (pyy, cholecystokinin ...) appetite feelings will be assessed throughout the day at regular interval using visual analogue scales.

Eligibility criteria:
inclusion criteria: * 12 to 15 years old adolescents * obese according to international values for bmi * being registered to the national social security insurance * no eating disorders * no medications * metabolic disorders exclusion criteria: * metabolic disorders * food disorders * physical disability
fluid management of acute decompensated heart failure subjects treated with reprieve decongestion management system (dms)

Conditions: Acute Decompensated Heart Failure

Summary: the objective of this study is to prospectively compare decongestive therapy administered by the reprieve dms system to optimal diuretic therapy (odt) in the treatment of patients diagnosed with acute decompensated heart failure (adhf). the main objective is to determine if the reprieve dms can more efficiently decongest adhf patients in comparison to control therapy.


Eligibility criteria:
inclusion criteria: 1. hospitalized with a diagnosis of heart failure as defined by the presence of at least 1 symptom and 1 sign. 2. ≥10 pounds (4.5 kg) above dry weight either by historical weights or as estimated by health care provider. 3. prior use of loop diuretics within 30 says prior to admission. 4. ≥ 18 years of age able to provide informed consent and comply with study procedures. exclusion criteria: 1. inability to place foley catheter or iv catheter. 2. hemodynamic instability. 3. dyspnea due primarily to non-cardiac causes. 4. acute infection with evidence of systemic involvement. 5. estimated glomerular filtration rate (egfr) \< 20 ml/min/1.73m2 calculated using the mdrd equation or current use of renal replacement therapy. 6. significant left ventricular outflow obstruction, uncorrected complex congenital heart disease, severe stenotic valvular disease, infiltrative or constrictive cardiomyopathy, acute myocarditis, type 1 acute myocardial infarction requiring treatment, or any other pathology that, in the opinion of the investigator, would make aggressive diuresis poorly tolerated. 7. inability to follow instructions or comply with follow-up procedures. 8. other concomitant disease or condition that investigator deems unsuitable for the study, including drug or alcohol abuse or psychiatric, behavioral or cognitive disorders, sufficient to interfere with the patient's ability to understand and comply with the study instructions or follow-up procedures. 9. severe electrolyte abnormalities. 10. presence of active coronavirus disease 2019 (covid-19) infection. 11. enrollment in another interventional trial during the index hospitalization. 12. inability to return for follow-up study visits. 13. life expectancy less than 3 months. 14. women who are pregnant or intend to become pregnant.
implementation and evaluation of a diabetes prevention clinical pathway in primary care

Conditions: PreDiabetes; Prediabetic State

Summary: prediabetes is a significant public health problem affecting 88 million u.s. adults. evidence suggest that the vast majority of people with prediabetes are unaware of having this condition and many are not receiving appropriate care for prediabetes, including referral to evidence-based programs like the diabetes prevention programs (dpp). in the investigator's retrospective cohort study of patients with prediabetes from johns hopkins health systems, the investigators found that the rates of prediabetes clinical care activities are low. in the investigators' qualitative studies, the investigators found that primary care physician (pcp) barriers include low knowledge about diabetes prevention programs and misperceptions of insurance coverage of these programs and inadequate clinical staff to address prediabetes. common patient barriers to taking action to prevent diabetes include lack of motivation, time and resources. based on prior research, comprehensive strategies are urgently needed to improve prediabetes care. using these findings, the investigators have designed and plan to implement a diabetes prevention clinical pathway which seeks to address some of these common clinician and patient barriers. the investigators hypothesize that the clinical pathway will result in increased clinician screening and intervention and improve patient engagement in diabetes prevention. the investigators will compare results from the intervention clinic compared to a control clinic. if successful, the investigators plan to implement and test the effectiveness of this clinical pathway across the entire health system.


Eligibility criteria:
inclusion criteria: * prediabetes based on prediabetes registry * age ≥ 18 years * pcp visit during intervention period * patient of johns hopkins green spring station (gss) general internal medicine or johns hopkins community physicians (jhcp) internal medicine clinic. exclusion criteria: * visit with clinician who's not their primary care physician (pcp)

Keywords: diabetes prevention primary care clinical pathway pragmatic intervention
a registry for nontuberculous mycobacterial pulmonary disease

Conditions: Nontuberculous Mycobacterial Pulmonary Disease

Summary: background: ntm(nontuberculous mycobacteria) pulmonary disease is increasing worldwidely, however the diagnosis and treatment of ntm pulmonary disease still has multiple obstacles. the initiation of treatment is not necessary for all patients with ntm pulmonary disease. in addition, the drugs for treatment of ntm pulmonary disease is not enough. objective. the aim of this prospective registry for nontuberculous mycobacterial pulmonary disease is to register the ntm pulmonary patients and analysis of the treatment outcome based on the species and to collect the blood and urine samples from the patients for exploring the biomarker for diagnosis and monitoring the ntm pulmonary disease and collect the nontuberculous mycobacterium. methods: 1. informed consents 2. register in cohort and collect the clinical information and serum, plasma, urine and mycobacteria 3. follow up 6 months to 1year based on the clinical situation analysis: 1. treatment outcome based on ntm-net consensus statement 2. exploration of biomarker for progression and monitoring of treatment response


Eligibility criteria:
inclusion criteria: 1. age 20 or more than 20 years 2. diagnosed by ats criteria for ntm pulmonary disease exclusion criteria: 1) not specific

Keywords: nontuberculous mycobacteria pulmonary cohort
aerial trial: antiplatelet therapy in heart transplantation

Conditions: Cardiac Allograft Vasculopathy; Heart Transplant

Summary: cardiac allograft vasculopathy is a common complication affecting heart transplant patients. this condition causes narrowing of the heart arteries leading to graft dysfunction. the research team is investigating whether early antiplatelet therapy post heart transplant can prevent the development of cav. this study will determine the feasibility of a large multicenter randomized placebo-controlled trial to answer this question.

heart transplant patients who fulfill selection criteria will undergo baseline clinical evaluation and data collection. participants will be randomized to either placebo, aspirin or clopidogrel to be taken daily for the duration of the study. patients will undergo invasive coronary studies (angiography, optical coherence tomography and intracoronary flow) and platelet function testing at 2 and 12 months post heart transplant. in addition, angiography will be performed at 24 months post heart transplant and thereafter according to institutional protocol. the primary analysis will determine the feasibility of conducting a large multicenter randomized placebo controlled trial by assessing recruitment rates, event rates, treatment crossovers and loss to follow-up. secondary analyses will include assessing the effect of antiplatelet treatment on angiographic cav, coronary intimal disease on optical coherence tomography, coronary macrovascular and microvascular function by intracoronary flow measures, and platelet function.

Eligibility criteria:
inclusion criteria: 1. heart transplant 2. age ≥18 years 3. able to provide informed consent exclusion criteria: 1. allergy or known intolerance to aspirin 2. allergy or known intolerance to clopidogrel 3. intracranial hemorrhage ≤14 days 4. bleeding disorder 5. platelet count \<50 x 109/l 6. history of aspirin related gastrointestinal bleeding or ulcers 7. non-cardiac indication for antiplatelet therapy 8. anticoagulation \>3 months 9. allergy to iodinated contrast 10. unable to undergo coronary angiography due to glomerular filtration rate ≤30 ml/min/1.73 m2 for non-dialysis patients 11. unable to undergo coronary angiography due to unsuitable vascular access 12. combined solid organ transplantation.
first-in-human study evaluating a novel catheter device in subjects with treatment-resistant hypertension

Conditions: Hypertension,Essential

Summary: the carotid body is located at the bifurcation of the internal and external carotid arteries. it is a chemoreceptor that plays a role in the sympathetic nervous system and in the development and maintenance of hypertension. hypertension is a major cardiovascular risk factor and is associated with coronary artery disease, stroke, chronic kidney disease, and heart failure. the objective of this study is to assess the effectiveness and safety of a catheter-based system to ablate the carotid body and reduce blood pressure (bp) in patients with resistant hypertension and to confirm sustainability of the treatment benefits long-term as seen following surgical cb removal.


Eligibility criteria:
inclusion criteria: * mean office sbp ≥160 mmhg and dbp ≥90 mmhg during screen-in period * mean daytime systolic abpm ≥135 mmhg during screen-in period * adherent to a stable drug regimen of three (3) or more anti-hypertensive medications of different classes (including one (1) diuretic), with no medication changes expected for at least six (6) months post-procedure * no change in anti-hypertensive drug prescription (dose, number of medications, or class of medication) for at least six (6) weeks prior to enrollment * negative pregnancy test for women of child-bearing age * willingness and able to comply with follow-up requirements * signed informed consent exclusion criteria: * secondary causes of hypertension * calculated egfr \<30ml/min/1.73m2 * history of repeated episodes of hypoglycemic unawareness * morbid obesity, defined as body mass index \>40 kg/m2 * severe obstructive sleep apnea (ahi \> 35/hr.) * pacemaker and/or implantable defibrillators * history of transient ischemic accident or cerebrovascular accident during six (6) months prior to screening * history of acute heart failure, congestive heart failure (nyha class iii-iv), myocardial infarction, unstable angina, coronary bypass or coronary angioplasty during six (6) months prior to screening * history of ipsilateral carotid endarterectomy treatment or ipsilateral carotid artery stenting
prenatal iron and malaria study

Conditions: Malaria

Summary: the purpose of this study is to compare the presence of plasmodium infection in parturient women who antenatally received a combination of iron-fortified foods with iron supplements versus iron-fortified foods only.

as per recommendations by the world health organization (who), iron supplementation in children should be restricted in malaria-endemic areas because of concerns that it can lead to an increased burden of malaria. universal iron supplementation continues to be recommended, however, for women during pregnancy and 3 months postpartum. observational studies have shown that iron deficiency in parturient women is associated with a marked reduction in the prevalence and density of malarial parasites in the placenta. plasmodium infections in pregnant women have devastating effects on the foetus and neonate, causing low birth weight, intrauterine growth retardation, preterm delivery, spontaneous abortion, stillbirth and neonatal mortality. based on our previous work, the kenyan government is currently drafting legislation for mandatory iron fortification of industrially milled flour. implementation of the new fortification policy means that pregnant women will receive iron through a combination of fortified foods and supplementation. the investigators are concerned about the safety of the high iron intake resulting from such a policy.

Eligibility criteria:
inclusion criteria: * women aged 15-45 years resident in the predefined study area * pregnant, with gestational age \<23 weeks exclusion criteria: * failure to provide a blood sample * initial haemoglobin concentration \<90 g/l * reported medical history suggestive of sickle cell anaemia, epilepsy, diabetes * obstetric history suggestive of eclampsia or pre-eclampsia * obvious mental retardation or metabolic disorder; * no written consent * carrying multiples * woman planning to leave the homestead or to be absent for prolonged periods in the course of the pregnancy or within a 1-month period thereafter * woman planning to deliver outside the research clinic.

Keywords: iron plasmodium malaria pregnancy kenya
docetaxel and s-1 in head and neck squamous cell carcinoma (hnscc)

Conditions: Head and Neck Squamous Cell Carcinoma

Summary: to assess response rate of docetaxel and s-1 combination in metastatic or recurrent head and neck squamous cell carcinoma


Eligibility criteria:
inclusion criteria: * histologically confirmed hnscc * adequate primary site: oral cavity, oropharynx, hypopharynx, nasal cavity, paranasal sinus, other head and neck site (except nasopharynx) * at least one measurable lesion * no previous palliative chemotherapy (adjuvant/neoadjuvant chemotherapy and/or radiotherapy longer than 6 months ago is permitted) * 18 years or older * ecog 0 or 1 * adequate laboratory result * written, informed consent exclusion criteria: * pregnant or lactating women (negative pregnancy test within 7 days is required for women with potential of child-bearing) * experimental drug clinical trial within 30 days * other malignancy (exemption: treated basal cell carcinoma of skin, cis, cured cancer with disease-free interval with more than 5 years) * patient with organ transplantation * grade 2 or more peripheral neuropathy * grade 2 or more hearing loss * severe, medical condition

Keywords: s-1 docetaxel head and neck cancer recurrent or metastatic head and neck squamous cell carcinoma
efficacy, safety and tolerability of ain457 in patients with rheumatoid arthritis (ra) taking methotrexate (mtx)

Conditions: Rheumatoid Arthritis

Summary: this study will assess at week 16 the efficacy and safety of ain457 at different doses in patients with active ra despite stable mtx therapy. treatment will continue up to week 48 with a safety follow-up at week 60 to assess the long term efficacy and safety of ain457 treatment in combination with mtx in ra.


Eligibility criteria:
inclusion criteria: * presence of ra classified by acr 1987 revised criteria. patients with active ra should have been on mtx for at least 3 months and must currently be treated with a stable dose of mtx (\> or =7.5 mg/week - \< or = 25 mg/week) for at least 4 weeks * at baseline: disease activity criteria defined by \> or = 6 out of 28 tender joints and \> or = 6 out of 28 swollen joints with either screening value of hscrp \> or = 10 mg/l or esr \> or = 28 mm/1st hr exclusion criteria: * ra patients functional status class iv classified according to the acr 1991 revised criteria * patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, or morphine) * any therapy by intra-articular injections (e.g. corticosteroid) required for treatment of acute ra flare within 4 weeks before randomization other protocol-defined inclusion/exclusion criteria may apply

Keywords: rheumatoid arthritis, ra, acr, inflammatory joints